Source: International Congress 2018 – Granulomatous disorders: heterogeneous diseases with variable management



Rating:

Share or cite this content

Citations should be made in the following way:
D. Gawryluk (Warsaw, Poland), J. Fijolek (Warsaw, Poland), E. Wiatr (Warsaw, Poland). Long-term outcomes of rituximab (RTX) therapy in recurrent Granulomatosis with Polyangiitis (GPA). 3009

Member's Comments

No comment yet.

Related content which might interest you: Effectiveness of rituximab (RTX) therapy in recurrent granulomatosis with polyangiitis (GPA) Source: International Congress 2016 – New and old therapies for chronic lung diseases Year: 2016 Lung-limited Granulomatosis with polyangiitis (GPA) managed without immunosuppression Source: International Congress 2018 – CC5 Pulmonary vasculitis: the great chameleon Year: 2018 Twelve month outcomes with Reslizumab treatment of Eosinophilic Granulomatosis with Polyangiitis Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Physiological characteristics in patients with microscopic polyangitis (MPA) and wegener‘s granulomatosis (WG) Source: Eur Respir J 2004; 24: Suppl. 48, 327s Year: 2004 Fatal haemoptysis in a case of lymphomatoid granulomatosis treated with rituximab Source: Eur Respir J 2006; 27: 644-646 Year: 2006 ANCA-negative eosinophilic granulomatosis with polyangiitis (EGPA) relatead to sirolimus-eluting stent Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects Year: 2015 Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis Source: Eur Respir J 2014; 43: 602-609 Year: 2013 Granulomatosis with polyangiitis (Wegener&s) Source: Eur Respir Mon 2011; 54: 1-14 Year: 2011 Long-term treatment with infliximab in patients with sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 Wegener's granulomatosis after Montelukast in patient not receiving systemic steroid treatment Source: Eur Respir J 2002; 20: Suppl. 38, 65s Year: 2002 Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis Source: ERJ Open Res, 6 (1) 00311-2019; 10.1183/23120541.00311-2019 Year: 2020 Asthma follow-up and treatment in a group of 28 patients with eosinophilic granulomatosis with polyangiitis (EGPA) Source: Annual Congress 2013 –Is it really asthma? Year: 2013 Wegener's granulomatosis (WG) - clinical features and response to treatment in 18 cases Source: Eur Respir J 2002; 20: Suppl. 38, 64s Year: 2002 Granulomatous lung disease in lymphoma patient after rituximab treatment Source: Virtual Congress 2020 – Interstitial lung diseases Year: 2020 Clinical and radiological correlation of pulmonary complications in CHOP versus rituximab-CHOP regimen treated non-Hodgkin’s lymphoma in Thailand Source: International Congress 2017 – Rare diseases Year: 2017 Early-onset therapy with sirolimus helps to improve prognosis of patients with lymphangioleiomyomatosis (LAM) Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases Year: 2019 Long-term follow-up in Churg-Strauss syndrome following IFN-α-induced remission Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Therapy with low dose methotrexate plus diprospan in patient with recalcitrant recidivating sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 541s Year: 2006 Combined cytotoxic treatment (methotrexate and cyclophosphamide) in association with prednisone in sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 713s Year: 2004 Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis Source: ERJ Open Res, 6 (4) 00451-2020; 10.1183/23120541.00451-2020 Year: 2020